5results about How to "Has inhibitory effect" patented technology

The invention discloses application of a siRNA composition in preparation of a medicine for treating liver diseases and the medicine. The siRNA composition at least comprises PCBP2-siRNA and PD-L1-siRNA. The invention discovers that PCBP2-siRNA and PD-L1-siRNA can effectively reduce type I collagen deposition in a mouse hepatic fibrosis model induced by CCL4 for the first time. The result shows that the two siRNAs both have a potential anti-fibrosis effect. And when the PCBP2-siRNA and the PD-L1-siRNA are used in a combined manner, the inhibition effect of the PCBP2-siRNA and the PD-L1-siRNA on the type I collagen deposition is more obvious than that of the PCBP2-siRNA which is independently used with any siRNA. The result shows that the liver fibrosis degree can be more effectively relieved through combined application of the two siRNAs.

The application provides artemordins A-S (compounds 1-19), a pharmaceutical composition thereof, and a preparation method and application thereof, and belongs to the technical field of drugs. The 19 sesquiterpene dimers shown in structural formula (I) of the application have cytotoxic activity on human hepatoma cell strains HepG2, Huh7 and SK-Hep-1, can be combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, and can be used for preparing an anti-hepatoma drug.

The present application relates to the technical field of microorganism, and especially relates to Enterococcus hirae C01, probiotic agent and application thereof.The present application provides the Enterococcus hirae C01, and the preservation number is CGMCC No.33994.The strain has broad-spectrum bacteriostatic activity, can inhibit Salmonella enteritidis, Salmonella pullorum and Salmonella typhimurium, has no hemolytic activity, has good stress resistance, can survive in gastrointestinal environment, and has high biological safety, and can be used for preventing and controlling mixed Salmonella infection in clinic.

This invention specifically relates to a composite polymer antibacterial agent, its preparation method, and its application, belonging to the field of antibacterial materials technology. The antibacterial agent, by weight percentage, comprises a core component PQ-1 (0.01%~0.1%), a synergistic component polyhexamethylene biguanide (PHMB) (0.005%~0.05%), a synergistic component polyaminopropyl biguanide (PAPB) (0.005%~0.05%), and the balance being solvent. This invention, through the synergistic combination of PQ-1 and the two synergistic components, can reduce the minimum inhibitory concentration (MIC) against typical microorganisms by more than 75% while reducing the amount of PQ-1 by 50%~80%, achieving optimized protection of the antibacterial efficacy concentration of PQ-1, while also possessing the advantages of broad spectrum, stability, mildness, and low toxicity. Its preparation process is simple and can be widely applied in ophthalmic preparations, cosmetics, and other fields, demonstrating extremely high practical value.

The method comprises the following steps: adding diacetyl into a water body to be treated, playing a role under the irradiation of sunlight, and inhibiting the growth of algae and fungi; the algae are skeletonema costatum, phaeocystis globosa, microcystis aeruginosa or prorocentrum donghaiense; the fungus is escherichia coli or staphylococcus aureus. According to the method, diacetyl is adopted as an active substance, the algal inhibition and sterilization effects can be achieved only under natural light, and the method is good in selectivity, environmentally friendly, economical, efficient and suitable for algal control and disinfection of shallow lakes, swimming pools, seawater / freshwater farms and landscape water bodies.